We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
- Authors
Dlouhy, Ivan; Torrente, Miguel; Lens, Sabela; Rovira, Jordina; Magnano, Laura; Giné, Eva; Delgado, Julio; Balagué, Olga; Martínez, Antonio; Campo, Elías; Forns, Xavier; Sánchez-Tapias, José; López-Guillermo, Armando; Torrente, Miguel Á; Giné, Eva; Balagué, Olga; Martínez, Antonio; Campo, Elías; Sánchez-Tapias, José M; López-Guillermo, Armando
- Abstract
Diffuse large B cell lymphoma (DLBCL) patients carrying hepatitis C virus (HCV) have higher risk of treatment toxicity and complications. The aim of this study was to assess the impact of HCV in a series of DLBCL patients treated with immunochemotherapy. 321 patients (161 M/160F; median age, 66 years) diagnosed with de novo DLBCL in a single center between 2002 and 2013 were included. Immunodeficiency-related lymphomas were excluded. HCV+ cases were defined by the presence of IgG anti-HCV. Main clinico-biological characteristics and outcome were analyzed according to the viral status. Two hundred ninety patients were HCV- and 31 HCV+. HCV+ patients were older (median age 71 vs. 64 years, P = 0.03), had more often B symptoms (P = 0.013), spleen (P = 0.003), and liver (P = 0.011) involvement, higher rate of early death (<4 months, P = .001), and shorter overall survival (OS). Eleven HCV+ patients had cirrhosis criteria. HCV+ patients with impaired liver function before or during treatment showed inferior OS. Elevated pre-treatment bilirubin correlated also with higher liver toxicity. In a multivariate analysis that included R-IPI score, serum beta2-microglobulin (β2m), HCV status, and presence of cirrhosis, only R-IPI, β2m, and cirrhosis showed independent prognostic impact on OS. The presence of HCV in DLBCL patients entails higher number of complications and early deaths; however, liver impairment and not the hepatitis viral status was the key feature in the outcome of the patients.
- Subjects
HEPATITIS C virus; DIFFUSE large B-cell lymphomas; HEPATOTOXICOLOGY -- Risk factors; CANCER treatment complications; CANCER immunotherapy; CANCER chemotherapy; IMMUNOGLOBULIN G; THERAPEUTICS; HEPATITIS C diagnosis; ANTINEOPLASTIC agents; B cell lymphoma; HEPATITIS C; HEPATITIS viruses; IMMUNOTHERAPY; LONGITUDINAL method; SURVIVAL; TREATMENT effectiveness; RETROSPECTIVE studies; DIAGNOSIS
- Publication
Annals of Hematology, 2017, Vol 96, Issue 3, p405
- ISSN
0939-5555
- Publication type
journal article
- DOI
10.1007/s00277-016-2903-8